Compared to many other activities, it’s quite resource-heavy, time-consuming, and expensive. But too often, teams pour everything into producing the data and then stop cold once the manuscript is submitted and the final report is filed. If that’s where your effort ends, you’re only halfway there.
The true value of RWE lies not just in the data you collect, but in how you use it. It’s the engine behind smarter decision-making, stronger partnerships, and better patient outcomes. Done right, RWE becomes one of the most strategic assets in your toolbox and one of the highest ROI activities pharma can invest in. Here’s how to unlock that value.
Build Collaboration That Matters
RWE answers real, pressing questions, such as:
- How do patients move through the healthcare system?
- What treatments are they receiving, and in what sequence?
- What outcomes and safety signals are emerging in day-to-day clinical use?
- What is the true burden of disease, both in direct healthcare expenses and productivity loss?
These are questions that matter not only to pharma but to healthcare professionals (HCPs), hospitals, payers, and policymakers alike. That’s why RWE is such a powerful foundation for collaboration.
Healthcare professionals are often eager to contribute to scientific work but lack the time or resources to do it alone. RWE studies offer a win-win setup. Pharma leads the heavy lifting — project management, analytics, and scientific expertise — while clinicians bring their insight, patient knowledge, and scientific curiosity. It’s a natural partnership that fosters trust and drives meaningful progress.
From Data to Dialogue
Even the best research doesn’t drive impact if no one sees it. You need a plan to communicate your results, not just in scientific journals, but in ways that reach your key audiences. Depending on the case, that could mean:
- Press releases and summaries tailored to the general public
- Scientific communications for HCPs, such as congress abstracts, posters, educational events, and congress presentations
- Tools for the field teams, like presentation decks, infographics, and data visualizations
- Multimedia assets including expert videos, animations, and newsletters
Local data is gold. HCPs are far more engaged when they see numbers from their own region, hospital, or even clinic. Bringing that local relevance into the discussion makes the science more meaningful and the engagement far more impactful.
Use RWE to Strengthen Market Access
In most cases, market access teams are the number one internal drivers for new RWE projects — and for good reason. You need to understand things like local treatment practices, real-world treatment outcomes, gaps in care, healthcare resource utilization, and cost-effectiveness.
Without this, building a credible access strategy or local health economic model might be almost impossible. Local RWE gives your value story real substance and provides the evidence your pricing and positioning need to stand up to scrutiny.
Support Development of Treatment Practices
Pharma isn’t just a supplier of medicines. It’s a knowledge partner. And in an era where treatments are evolving fast, the development must be grounded in data.
RWE offers the opportunity to collaborate on evidence-based improvements in clinical practice. Alongside data expertise, pharma teams bring essential capabilities to these initiatives, including project management, scientific knowledge, and communication tools.
Start With the End in Mind
The most impactful real-world evidence studies have a clear plan for how the data will be used right from the start. Before you proceed with data collection, make sure you can answer:
- Why are we generating this data?
- How will it be used when it’s ready?
- Who will need it and when?
Work with a vendor who doesn’t just run the study, but also understands how to drive impact afterward. That could mean aligning your research, communication, education, and access strategy from the very start. When the transition from data generation to data activation is seamless, results don’t sit in a drawer but go to work.
Real-world evidence isn’t just a research activity. It’s a shared interest across pharma, healthcare professionals, healthcare organizations, and payers. It creates an opportunity for true collaboration where everyone wins. This is one of the clearest ways pharma can deliver real value to healthcare and society beyond just producing pills.
